RCK

Company Overview

Snapshot

Founded in January 2016 by Noam Chehanovsky and David Gabay, RCK operates with 11–50 employees. The company has raised $700,000 across one funding round. In February 2021, RCK signed a multi-million dollar deal with SeedTech, a Dutch cannabis genetics company.

Business overview

RCK specializes in breeding repeatable and stable hybrid cannabis seeds for both medical and recreational markets. The company aims to advance cannabis agriculture through methodological, marker-assisted breeding and proprietary technologies. RCK holds licenses for the entire production chain, including growing, processing, distribution, and R&D, serving the medical cannabis and agricultural technology sectors.

Strategic signal

In February 2021, RCK signed a multi-million dollar deal with SeedTech, a Dutch cannabis genetics company. This collaboration signifies a significant market validation for RCK's cannabis breeding technologies and opens new avenues for international market expansion and product development, indicating strong commercial momentum.

Company Intelligence Q&A

What is RCK's core business?

RCK breeds repeatable and stable hybrid cannabis seeds for medical and recreational markets, utilizing methodological, marker-assisted cannabis breeding and proprietary technologies.

When was RCK founded and by whom?

RCK was founded in January 2016 by Noam Chehanovsky and David Gabay.

What significant partnership did RCK announce in February 2021?

In February 2021, RCK signed a multi-million dollar deal with SeedTech, a cannabis genetics company based in Holland.

What was the nature of the collaboration between RCK and Cannabics Pharmaceuticals?

In February 2020, Cannabics Pharmaceuticals collaborated with RCK to develop cannabis strains specifically targeting gastrointestinal cancers.

What was the outcome of the collaboration between NRGene and RCK?

In September 2018, NRGene and RCK partnered to develop DNA tests for medical cannabis.